Neonatology

Original Paper

Cerebrospinal Fluid and Serum Nitric Oxide Levels in Asphyxiated Newborns

Ergenekon E.a · Gücüyener K.b · Erbaş D.c · Süheyl Ezgü F.a · Atalay Y.a

Author affiliations

Department of Pediatrics,aDivision of Newborn Medicine; bDivision of Pediatric Neurology, and cDepartment of Physiology, Gazi University, Ankara, Turkey

Related Articles for ""

Biol Neonate 1999;76:200–206

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: September 03, 1999
Issue release date: October 1999

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 2

ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)

For additional information: https://www.karger.com/NEO

Abstract

Hypoxic-ischemic encephalopathy (HIE) is the result of a chain of events caused mainly by cytokines and nitric oxide (NO) release, which is later on followed by free oxygen radical injury. To investigate NO involvement in asphyxiated newborns, serum and cerebrospinal fluid (CSF) values of NO levels in 17 neonates with HIE were detected. Infants at or above 37 weeks of gestation were classified to have mild, moderate and severe HIE due to Sarnat and Sarnat. Samples obtained between 24 and 72 h of life were immediately frozen at –70°C till the time of measurement by Sievers NOA. Five patients had mild, 6 patients had moderate and 6 patients had severe HIE, 4 in the severe HIE group also had multisystem involvement. The CSF NO levels were significantly higher in moderate and severe HIE groups compared to the mild HIE group (p = 0.028 and p = 0.018 respectively). Our results show that NO level increases in CSF with the severity of HIE between 24 and 72 h following asphyxia. According to the animal work, this is the time period where inducible NO synthase gets activated and could cause neurotoxicity, which might perhaps be prevented by interventions.




Related Articles:


References

  1. Volpe JJ: Neurology of the Newborn, ed 3. Philadelphia, Saunders, 1995, pp 221–239, 331–363.
  2. du Plessis AJ, Johnson VM: Hypoxic-ischemic brain injury in the newborn. Cellular mechanisms and potential strategies for neuroprotection. Neurologic disorders in the newborn. 1. Clin Perinatol 1997;24:627.
    External Resources
  3. Fellman V, Raivivo OK: Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Pediatr Res 1996;41:599–606.
  4. Moskowitz AM, Dalkara T: Nitric oxide and cerebral ischemia; in Siesjö BK, Tadeusz W (eds): Cellular and Molecular Mechanics of Ischemic Brain Damage. Adv Neurol Philadelphia, Lippincott-Raven, 1996, vol 71, pp 365–369.
  5. Meldrum BS: The role of nitric oxide in ischemic damage; in Siejsö BK, Tadeusz W (eds): Cellular and Molecular Mechanics of Ischemic Brain Damage. Adv Neurol Philadelphia, Lippincott-Raven, 1996, vol 71, pp 355–363.
  6. Iadecola C: Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997;20:132–139.
  7. Sarnat HB, Sarnat MS: Neonatal encephalopathy following fetal distress. Arch Neurol 1976;33:696–705.
  8. Brahman RS, Hendrix SA: Nanograms nitrite and nitrate in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Analyt Chem 1989;61:2715–2718.
  9. Weiner LI, Knowles RE, Moncada S: The ontogeny of cerebral and cerebellar nitric oxide synthase in the guinea pig and rat. Pediatr Res 1996;39:779–783.
  10. Northington FJ, Tobin JR, Traytsman RJ, Koehler RC: Development and regional differences in nitric oxide synthase activity and blood flow in the sheep brain. J Cereb Blood Flow Metab 1997;7:109–115.
  11. Keelan J, Brand MP, Bates TE, Land JM, Clark JB, Heales SJ: Nitrix oxide and antioxidant status in glucose and oxygen-deprived neonatal and adult rat brain synaptosomes. Neurochem Res 1996;21:923–927.
    External Resources
  12. Ferreiero DM, Holtzman DM, Black SM, Sheldon RA: Neonatal mice lacking neuronal nitric oxide synthase are less vulnerable to hypoxic ischemic injury. Neurobiol Dis 1996;3:64–71.
  13. Higuchi Y, Hattori R, Farusho K: Increased neurons containing neuronal nitric oxide synthase in the brain of a hypoxic ischemic rat model. Brain Dev 1996;18:369–375.
  14. Dorrepaal CA, Shodid M, Steendijk P, Van der Velde ET, Van de Bor M, Baan J: Effect of post-ischemic inhibition of nitric oxide on cerebral blood flow, metabolism and electrocortical activity in newborn lambs. Biol Neonate 1997;72:216–226.
  15. Dalkara T, Moskowitz AM: Neurotoxic and Neuroprotective Roles of Nitric Oxide in Cerebral Ischemia. Neuroprotective Agents and Cerebral Ischemia. New York, Academic Press, 1997, pp 319–336.
  16. Samdnai AF, Dawson TM, Dawson VL: Nitric oxide synthase in models of focal ischemia. Stroke 1997;28:1283–1288.
  17. Beckman JS, Ye YZ, Chen J: The interactions of nitric oxide with oxygen free radicals and scavengers in cerebral ischemic injury; in Siesjö BK, Tadeusz W (eds): Cellular and Molecular Mechanics of Ischemic Brain Damage. Adv Neurol Philadelphia, Lippincott-Raven, 1996, vol 71, pp 339–350.
  18. Milotien S, Sakai N, Hayes MP: Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. J Neurochem 1994;63:1178–1180.
  19. Kuiper AM, Visser JJ, Bergman MLP, Scheltens P, Wolters CE: Decreased cerebrospinal fluid nitrate levels in Parkinson’s disease, Alzheimer’s disease and multiple system atrophy patients. J Neurol Sci 1994;121:46–49.
  20. Ashara H, Yoko I, da Tama T, Kabuto H, Ogawab N, Mori A, Ionoue H: Increased cerebrospinal fluid nitrite and nitrate levels in patients with lumbar spondylosis. Res Commun Mol Pathol Pharmacol 1996;91:77–83.
    External Resources
  21. Giovannoni G: Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult Scler 1998;4:27–30.
    External Resources
  22. Shi Y, Li HQ, San CK, Wang HJ, Qin WS, Liu R, Pan J: Plasma nitric oxide levels in newborn infants with sepsis. J Pediatr 1993;123:435–438.
  23. Ochoa JB, Udekwu AO, Billiar TR, et al: Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991;214:621–626.
  24. Wong RH, Carcillo AJ, Burckart G, Kaplan S: Nitric oxide production in critically ill patients. Arch Dis Chil 1996;74:482–489.
  25. Endo A, Shimada M, Ayusawa M, Minato M, Takada M, Takahashi S: Nitric oxide and endothelin-1 during postnatal life. Biol Neonate 1996;70:15–20.
  26. Kornelisse FR, Hoekman K, Visser JJ, Hop CW, Huijmans MGJ, Straten Vander JP, van der Heijden JA, Sukhai NK, Neijens JH, Groot R: The role of nitric oxide in bacterial meningitis in children. J Infect Dis 1996;174:120–126.
  27. Lawson LJ, Perry VH, Dri P, Gordon S: Heterogeneity in the normal and adult mouse brain. Neuroscience 1990;39:151–170.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: September 03, 1999
Issue release date: October 1999

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 2

ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)

For additional information: https://www.karger.com/NEO


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP